Pharmacokinetics, safety, and tolerability of the 2‐ and 3‐direct‐acting antiviral combination of AL‐335, odalasvir, and simeprevir in healthy subjects

This Phase I, open‐label, two‐group, fixed‐sequence study evaluated the pharmacokinetics and safety of AL‐335, odalasvir, and simeprevir in healthy subjects. Group 1 (n = 16) received AL‐335 800 mg once daily (QD) (days 1‐3, 11‐13, and 21‐23), simeprevir 150 mg QD (days 4‐23), and odalasvir 150 mg (...

Descripción completa

Detalles Bibliográficos
Autores principales: Kakuda, Thomas N., McClure, Matthew W., Westland, Christopher, Vuong, Jennifer, Homery, Marie‐Claude, Poizat, Gwendoline, Viguerie, Laure, Denot, Caroline, Patat, Alain, Zhang, Qingling, Hui, James, Apelian, David, Smith, David B., Chanda, Sushmita M., Fry, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5927802/
https://www.ncbi.nlm.nih.gov/pubmed/29736243
http://dx.doi.org/10.1002/prp2.395

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5927802/
https://www.ncbi.nlm.nih.gov/pubmed/29736243
http://dx.doi.org/10.1002/prp2.395

Ejemplares similares